Anti-met antibodies and uses thereof
AssigneeAgomab Therapeutics Bvba
InventorPaolo MICHIELI
Life of this patent
Estimating the term…
Abstract
The invention relates to agonistic anti-MET antibodies and uses thereof in the therapeutic treatment of disease. The antibodies bind with high affinity to the human and mouse hepatocyte growth factor (HGF) receptor, also known as MET, and are agonists of MET in both humans and mice, producing molecular and cellular effects resembling the effects of HGF binding.
Claims28
1-60. (canceled)
An antibody, or an antigen binding fragment thereof, which binds human MET protein (hMET) with high affinity and binds mouse MET protein (mMET) with high affinity, wherein the antibody or an antigen binding fragment thereof is a hMET agonist and a mMET agonist.
An antibody or antigen binding fragment thereof which recognizes an epitope of human MET located in a region from amino acid residue 123 to residue 223 of human MET, from amino acid residue 224 to residue 311 of human MET, from residue 314 to residue 372 of human MET or from residue 546 to residue 562 of human MET.
An antibody or antigen binding fragment which comprises a heavy chain variable domain comprising H-CDR1, H-CDR2 and H-CDR3, and a light chain variable domain comprising L-CDR1, L-CDR2 and L-CDR3, wherein:
- H-CDR1 comprises the amino acid sequence shown as SEQ ID NO:44,
- H-CDR2 comprises the amino acid sequence shown as SEQ ID NO:46,
- H-CDR3 comprises the amino acid sequence shown as SEQ ID NO:48,
- L-CDR1 comprises the amino acid sequence shown as SEQ ID NO:121,
- L-CDR2 comprises the amino acid sequence shown as SEQ ID NO:123, and
- L-CDR3 comprises the amino acid sequence shown as SEQ ID NO:125.
An antibody or antigen binding fragment which comprises a heavy chain variable domain comprising H-CDR1, H-CDR2 and H-CDR3, and a light chain variable domain comprising L-CDR1, L-CDR2 and L-CDR3, wherein:
- H-CDR1 comprises the amino acid sequence shown as SEQ ID NO:30,
- H-CDR2 comprises the amino acid sequence shown as SEQ ID NO:32,
- H-CDR3 comprises the amino acid sequence shown as SEQ ID NO:34,
- L-CDR1 comprises the amino acid sequence shown as SEQ ID NO:107,
- L-CDR2 comprises the amino acid sequence shown as SEQ ID NO:109, and
- L-CDR3 comprises the amino acid sequence shown as SEQ ID NO:111.
An antibody or antigen binding fragment which comprises a heavy chain variable domain comprising H-CDR1, H-CDR2 and H-CDR3, and a light chain variable domain comprising L-CDR1, L-CDR2 and L-CDR3, wherein:
- H-CDR1 comprises the amino acid sequence shown as SEQ ID NO:9,
- H-CDR2 comprises the amino acid sequence shown as SEQ ID NO:11,
- H-CDR3 comprises the amino acid sequence shown as SEQ ID NO:13,
- L-CDR1 comprises the amino acid sequence shown as SEQ ID NO:86,
- L-CDR2 comprises the amino acid sequence shown as SEQ ID NO:88, and
- L-CDR3 comprises the amino acid sequence shown as SEQ ID NO:90.
Dependencies are inferred from the claim text.